Nasopharyngeal Carcinoma Treatment
Nasopharyngeal Carcinoma Treatment
Treatment is built on radiotherapy, because this tumour is unusually radiosensitive and because of where it sits. Chemotherapy is added for locally advanced disease, sometimes before radiotherapy; surgery is kept for residual nodes and selected recurrences.
Treatment at a glance
The plan follows the stage, and radiotherapy appears in every curative option:
- Stage I — intensity-modulated radiotherapy alone, to the nasopharynx and the neck.
- Stage II — radiotherapy, with concurrent chemotherapy in many cases and especially where the nodal disease is bulky.
- Stage III — concurrent chemoradiotherapy; induction chemotherapy before it is considered when the tumour or the nodes are extensive.
- Stage IVA — induction chemotherapy followed by concurrent chemoradiotherapy, which is the standard approach where the tumour has reached the skull base, the cranial nerves or the orbit.
- Stage IVB — systemic treatment, including a PD-1 inhibitor, with radiotherapy used to control specific symptomatic sites.
- Residual disease in the neck — a neck dissection some weeks after radiotherapy, once the tumour has had time to respond.
- Local recurrence — decided case by case: endoscopic nasopharyngectomy, re-irradiation with a highly conformal technique, or systemic therapy.
Radiotherapy: the backbone of curative treatment
Nasopharyngeal carcinoma responds to radiation in a way that most head and neck cancers do not, and it sits in a position where an operation would put the skull base, the cranial nerves and the temporal lobes at risk. Both facts point the same way: radiotherapy is the treatment that cures this disease, and the question is not whether to use it but how precisely to deliver it.
Intensity-modulated radiotherapy is the standard technique. Instead of a few broad beams, it uses many small fields whose intensity is modulated so that the dose conforms to the shape of the tumour and the at-risk tissue while falling steeply outside it. The reason that matters here is the list of structures immediately around the target: the parotid glands that make saliva, the brainstem, the optic nerves and chiasm, the temporal lobes and the cochleae. With older techniques, permanent dry mouth was an expected consequence of cure. With IMRT planned well, the dose to the parotid can be kept below the threshold at which it stops working, and many patients retain useful saliva.
Treatment is given daily over roughly six to seven weeks, usually as an outpatient. Volumetric arc therapy is an alternative delivery method with similar conformality and shorter sessions. The plan is drawn directly on the diagnostic MRI, which is one of the reasons a high-quality MRI at the outset matters so much: it becomes the map for the treatment.
Concurrent chemotherapy: cisplatin during radiotherapy
For locally advanced disease, chemotherapy given during radiotherapy improves both local control and survival compared with radiotherapy alone, and cisplatin is the drug that has been used in the trials that established this. It is given on a three-weekly schedule in most protocols, or weekly at a lower dose in patients who tolerate the three-weekly schedule poorly.
The combination is effective and it is demanding. The acute side effects of radiotherapy — mucositis, pain, poor intake, weight loss — are worse when cisplatin is given at the same time, and the drug adds its own: kidney injury, hearing loss, nerve damage and a fall in blood counts. That means the decision to add chemotherapy is not automatic, and it is made on the basis of stage, age, kidney function and hearing. Baseline audiometry and creatinine clearance are taken before treatment starts precisely so that a change during treatment can be attributed correctly and the dose adjusted.
Induction chemotherapy before radiotherapy
Induction chemotherapy is given before chemoradiotherapy, with the aim of shrinking the tumour before the definitive treatment begins. In nasopharyngeal carcinoma the rationale is stronger than in most cancers, because the tumour is chemotherapy-sensitive and because a smaller tumour makes the radiotherapy plan easier to deliver safely.
The regimen used most widely is gemcitabine with cisplatin, on the basis of trials showing an improvement in survival when it is added before chemoradiotherapy in locoregionally advanced disease; a taxane-platinum combination is an alternative, and the choice between them is made on the patient's fitness and the toxicity profile. Induction is generally offered to Stage III and IVA disease, particularly where the tumour volume or the nodal bulk is large. It does not replace concurrent chemoradiotherapy — it precedes it — and it adds weeks to the overall treatment time, which is why the plan should be settled before travel rather than assembled during it.
Surgery: what it is for, and what it is not for
Surgery is not the treatment for the primary tumour at diagnosis, and this is the point patients most often arrive with a misconception about. The nasopharynx is a small space immediately beneath the skull base, surrounded by the optic chiasm, the temporal lobes and the cranial nerves, and the tumour is radiosensitive. An operation there would risk structures that a good radiotherapy plan protects, for a disease that radiotherapy controls.
Where surgery does belong is in two specific situations:
- A node that persists in the neck after radiotherapy — treated with a planned neck dissection, usually some weeks to a few months later, once the tumour has had time to respond. This is most often the case when nodal disease was bulky at the outset.
- Selected local recurrence — removed through the nose with an endoscope. Endoscopic nasopharyngectomy has become established for small, accessible recurrences, and it avoids a second course of high-dose radiation in a region that has already received a full dose.
A third, less common role exists where a recurrence involves the neck and cannot be controlled by irradiation alone. In every case the decision comes after imaging and after discussion, not at diagnosis.
Immune therapy and systemic treatment
Nasopharyngeal carcinoma is a virus-driven cancer, and that partly explains why it responds to immune checkpoint inhibition. PD-1 inhibitors are active in recurrent and metastatic disease, and several agents in this class were developed and approved in China; they have become a standard part of treatment for disease that has spread or returned, often combined with chemotherapy in the first line.
Beyond immunotherapy, systemic treatment means platinum-based chemotherapy, with a taxane or gemcitabine depending on what has been given before. The role of chemotherapy is different in the two settings: before or during radiotherapy it is given with curative intent, whereas in metastatic disease it is given to control the disease and prolong life. Targeted agents such as an anti-EGFR antibody are used in some centres. What is not yet established is giving a PD-1 inhibitor routinely in earlier-stage disease, which is the subject of ongoing trials — so it should not be presented as a standard option for a newly diagnosed early tumour.
When it comes back
Recurrence in nasopharyngeal carcinoma is usually detected either by a rising plasma EBV DNA level or on MRI, and where it is found determines what can be done about it. Two patterns matter.
A recurrence in the neck after radiotherapy is often operable, and a neck dissection in that setting can be curative. A recurrence at the primary site is harder: surgery is possible in selected small tumours through an endoscopic approach, and re-irradiation is possible with modern conformal techniques, but the two have to be weighed against each other. Re-irradiation of a nasopharynx that has already received a full dose carries a real risk of damage to the temporal lobes, cranial nerves and bone, and the techniques used to reduce it — highly conformal photon planning, stereotactic delivery, and in some centres proton therapy — exist precisely because the margin for error is small. The choice between surgery, re-irradiation and systemic treatment is made jointly, and it depends on the size and position of the recurrence and on how the tissue has changed since the first treatment.
How the decision is actually made
Nasopharyngeal carcinoma is planned jointly by radiation oncology and medical oncology, with radiology, pathology and — where recurrence or surgery is in question — head and neck surgery alongside them. The reason this matters more here than in some cancers is that all three treatment modalities can be involved in one patient, and the sequencing is not interchangeable: induction chemotherapy before chemoradiotherapy is not the same treatment as the same drugs given after it.
In practice, the discussion settles three things: whether chemotherapy is added to radiotherapy at all, whether induction chemotherapy is given before it, and how the radiotherapy target is drawn given the skull-base findings. Because the radiotherapy plan is drawn on the diagnostic MRI, the discussion happens before the first fraction rather than during the course. Send complete records and the written assessment is returned within 48 hours of the file being complete.